Have a feature idea you'd love to see implemented?
Let us know!
VRTX Vertex Pharmaceuticals Inc
Price (delayed)
$474.375
Market cap
$122.44B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.89
Enterprise value
$118.79B
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather
Highlights
VRTX's revenue is up by 9% YoY
The gross profit has grown by 7% YoY
Vertex Pharmaceuticals's net income has shrunk by 115% YoY and by 112% QoQ
The EPS has dropped by 114% year-on-year and by 112% since the previous quarter
Key stats
What are the main financial stats of VRTX
Market
Valuations
Earnings
Shares outstanding
258.1M
Market cap
$122.44B
Enterprise value
$118.79B
Price to book (P/B)
8.29
Price to sales (P/S)
11.84
EV/EBIT
463.12
EV/EBITDA
255.41
EV/Sales
11.49
Revenue
$10.34B
EBIT
$256.5M
EBITDA
$465.1M
Free cash flow
-$1.18B
Per share
Balance sheet
Liquidity
EPS
-$1.89
Free cash flow per share
-$4.57
Book value per share
$57.25
Revenue per share
$40.05
TBVPS
$70.54
Total assets
$20.13B
Total liabilities
$5.36B
Debt
$933.4M
Equity
$14.77B
Working capital
$5.39B
Debt to equity
0.06
Current ratio
2.52
Quick ratio
2.1
Net debt/EBITDA
-7.84
Margins
Efficiency
Dividend
EBITDA margin
4.5%
Gross margin
86.4%
Net margin
-4.7%
Operating margin
-3.8%
Return on assets
-2.2%
Return on equity
-2.9%
Return on invested capital
3%
Return on capital employed
1.5%
Return on sales
2.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRTX stock price
How has the Vertex Pharmaceuticals stock price performed over time
Intraday
0.85%
1 week
0.92%
1 month
2%
1 year
32.71%
YTD
16.59%
QTD
2%
Financial performance
How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$10.34B
Gross profit
$8.94B
Operating income
-$397.3M
Net income
-$489.9M
Gross margin
86.4%
Net margin
-4.7%
Vertex Pharmaceuticals's net income has shrunk by 115% YoY and by 112% QoQ
VRTX's net margin has shrunk by 113% YoY and by 112% QoQ
The operating income has dropped by 110% year-on-year and by 110% since the previous quarter
The operating margin has shrunk by 109% QoQ and by 109% YoY
Growth
What is Vertex Pharmaceuticals's growth rate over time
Valuation
What is Vertex Pharmaceuticals stock price valuation
P/E
N/A
P/B
8.29
P/S
11.84
EV/EBIT
463.12
EV/EBITDA
255.41
EV/Sales
11.49
The EPS has dropped by 114% year-on-year and by 112% since the previous quarter
The stock's price to book (P/B) is 28% more than its last 4 quarters average of 6.4 and 23% more than its 5-year quarterly average of 6.7
The equity has contracted by 20% from the previous quarter and by 4.5% YoY
The price to sales (P/S) is 20% more than the 5-year quarterly average of 9.8 and 11% more than the last 4 quarters average of 10.6
VRTX's revenue is up by 9% YoY
Efficiency
How efficient is Vertex Pharmaceuticals business performance
VRTX's return on assets has dropped by 112% since the previous quarter and by 112% year-on-year
The return on equity has dropped by 112% since the previous quarter and by 112% year-on-year
The return on invested capital has dropped by 97% year-on-year and by 95% since the previous quarter
The return on sales has dropped by 95% since the previous quarter and by 95% year-on-year
Dividends
What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRTX.
Financial health
How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's quick ratio has decreased by 45% YoY and by 33% QoQ
Vertex Pharmaceuticals's current ratio has decreased by 39% YoY and by 28% from the previous quarter
VRTX's debt is 94% lower than its equity
The debt to equity has soared by 50% QoQ and by 20% YoY
VRTX's debt is up by 29% QoQ and by 22% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.